The Hindu Business Line : 2 Lupin drugs enter clinical trials

LUPIN Ltd today announced that it has received approval from the Drug Controller-General of India (DCGI) for conducting phase I clinical trials for two of its Investigational New Drug (IND) candidates, LL4858 (Sudoterb) and LL 4218 (Desoside-P).

With the addition of these two approvals, Lupin now has 4 IND applications approved by the DGCI. In pre-clinical studies, the anti-TB drug candidate LL 4858 was seen to significantly shorten the duration of treatment with low adverse effects as compared to existing anti-TB therapy. With the IND approval, LL 4858 will now enter phase I clinical trials in India.

More Stories on : Announcements | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
REL to bid for coal-based project in UP

Charak Pharma to set up ayurvedic clinics

2 Lupin drugs enter clinical trials

Strides arm to develop drug for US co Able

HC reserves verdict in caveat discharge plea by Lodha

Reliance Info contests DoT penalty

Court nod for Maharashtra Apex repayment scheme

Online directory to aid disabled kids

Govt puts $500-m cap on FII investments in corporate debt

IOC eyes stake in three Nigerian refineries

Monnet Ispat keen to acquire manganese ore mine abroad

Kerala petrochem project — GAIL to conduct feasibility study

India Inc makes inroads into Africa — Auto majors, pharma cos join the fray

Asian Venture Forum from Dec 6

Ester Industries out of BIFR's purview

Aluflouride plans to repay debts

Bata targets 12 pc rise in sales, plans another VRS